British pharmaceutical company GSK announced it will acquire cancer drug developer Nuvalent for $10.6 billion. This deal caused Nuvalent's stock to surge 39% as investors reacted positively to the acquisition. The move highlights GSK's strategic investment in cancer treatments, potentially strengthening its position in the oncology market. Further details on the deal's impact and timeline are expected as the acquisition progresses.
GSK has agreed to acquire US biotech firm Nuvalent for $10.6 billion (£8 billion) to enhance its oncology portfolio with advanced lung cancer treatments and other assets. The deal includes late-stage drugs zidesamtinib and neladalkib, both under FDA ...
UK pharmaceutical company GSK is negotiating to acquire oncology biotech Nuvalent for more than $9 billion, potentially finalizing the deal this week. This acquisition would be GSK's largest in over ten years and marks a shift from its recent smaller...
